The ROE as of September 2024 (TTM) for Cytokinetics, Incorporated (CYTK) is 196.01%

According to Cytokinetics, Incorporated’s latest financial reports and current stock price. The company's current ROE is 196.01%. This represents a change of -2486.06% compared to the average of -8.21% of the last 4 quarters.

Cytokinetics, Incorporated (CYTK) Historical ROE (quarterly & annually)

How has CYTK ROE performed in the past?

The mean historical ROE of Cytokinetics, Incorporated over the last ten years is 104.86%. The current 196.01% ROE has changed 86.92% with respect to the historical average. Over the past ten years (40 quarters), CYTK's ROE was at its highest in in the September 2022 quarter at 1.10%. The ROE was at its lowest in in the March 2019 quarter at -870.88%.

Cytokinetics, Incorporated (CYTK) ROE by Quarter and Year

Discovering the peaks and valleys of Cytokinetics, Incorporated ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cytokinetics, Incorporated (CYTK) Average ROE

How has CYTK ROE performed in the past?

The current ROE of Cytokinetics, Incorporated (CYTK) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Cytokinetics, Incorporated (CYTK) ROE vs. Peers

How is CYTK’s ROE compared to its peers?

Cytokinetics, Incorporated’s ROE is greater than DICE Therapeutics, Inc. (-102.37%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Karuna Therapeutics, Inc. (-30.79%), greater than Dyne Therapeutics, Inc. (-68.85%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Revolution Medicines, Inc. (-34.57%), greater than Relay Therapeutics, Inc. (-43.66%), greater than Black Diamond Therapeutics, Inc. (-69.08%), greater than Arvinas, Inc. (-55.59%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Blueprint Medicines Corporation (-85.25%),

Build a custom stock screener for Cytokinetics, Incorporated (CYTK) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cytokinetics, Incorporated using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cytokinetics, Incorporated (CYTK) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cytokinetics, Incorporated or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.